SCHEMBL1427754

SCHEMBL1427754

COc1cccc(N(C)C)c1CN1CCC(N)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 2/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CACNA1B Q00975 2/20 0.39
▸ HTT P42858 1/20 0.38
▸ BCHE P06276 2/20 0.37
▸ ACHE P22303 1/20 0.37
▸ BACE1 P56817 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ CACNA1C Q13936 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ GNAI3 P08754 1/20 0.36
▸ CD274 Q9NZQ7 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ CHRM5 P08912 1/20 0.36
▸ CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427991 1.00 TACR1 (0.40) TACR1MEN1KMT2AL3MBTL1CACNA1B
SCHEMBL1427752 1.00 TACR1 (0.40) TACR1MEN1KMT2AL3MBTL1CACNA1B
SCHEMBL9911770 0.92 CACNA1B (0.42) MEN1KMT2ACACNA1BBCHEACHE
SCHEMBL1427827 0.90 BRD4 (0.42) TACR1MEN1KMT2AL3MBTL1CACNA1B
Trifluoroacetic Acid SCHEMBL1428517 0.82 CACNA1B (0.44) MEN1KMT2AL3MBTL1CACNA1BHTT
SCHEMBL13627363 0.80 POLB (0.47) MEN1KMT2AKDM4EMAPK1SMN1; SMN2
SCHEMBL4205973 0.80 CACNA1B (0.39) MEN1KMT2ACACNA1BCACNA1CHTR7
SCHEMBL4187783 0.80 MEN1 (0.48) TACR1MEN1KMT2AL3MBTL1CACNA1B
SCHEMBL1428215 0.79 DRD2 (0.43) HTR7SMN1; SMN2
SCHEMBL4199069 0.78 DRD4 (0.48) BCHEACHEBACE1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193203-B2 Bicyclic compounds having activity at the CXCR4 receptor ALLERGAN, INC. (US) 2012-06-05 — — US disclosed
EP-2300456-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR Allergan, Inc. (US) 2011-03-30 — — EP disclosed
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-12-17 — — US disclosed
WO-2009143058-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR CXCR4, CXCR2, CXCL12 TACR1 70/4885MEN1 4354/4885KMT2A 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback